Brief: Fusion Pharmaceuticals Announces First Patient Dosed In Phase 1 Study Of FPI-2059, A Targeted Alpha Therapy (Tat) For The Treatment Of Solid Tumors Expressing Ntsr1
20/03/2023 20:08
March 20 (Reuters) - Fusion Pharmaceuticals Inc
FUSN.O :
* FUSION PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN
PHASE 1
STUDY OF FPI-2059, A TARGETED ALPHA THERAPY (TAT) FOR THE
TREATMENT OF SOLID TUMORS EXPRESSING NTSR1
Source text for Eikon: ID:nCNWNhRdZa
Further company coverage: FUSN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusion Pharmaceuticals
See all newsBrief: Acquisition Of Fusion Pharmaceuticals Completed
Brief: Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Fusion Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary